Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer

被引：11

作者：

Findlay, J. M. ^{[1
,2
]}

Bradley, K. M. ^{[3
]}

Wang, L. M. ^{[2
,4
]}

Franklin, J. M. ^{[3
]}

Teoh, E. J. ^{[3
]}

Gleeson, F. V. ^{[3
]}

Maynard, N. D. ^{[1
]}

Gillies, R. S. ^{[1
]}

Middleton, M. R. ^{[2
,5
]}

机构：

[1] Univ Oxford, Oxford OesophagoGastr Ctr, Oxford, England

[2] Univ Oxford, Nat Inst Hlth Res, Oxford Biomed Res Ctr, Oxford, England

[3] Univ Oxford, Churchill Hosp, Dept Nucl Med, Oxford, England

[4] Univ Oxford, John Radcliffe Hosp, Dept Pathol, Oxford, England

[5] Univ Oxford, Dept Oncol, Oxford, England

来源：

BRITISH JOURNAL OF SURGERY | 2017年 / 104卷 / 04期

关键词：

D O I：

10.1002/bjs.10435

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background: The ability to predict recurrence and survival after neoadjuvant chemotherapy (NAC) and surgery for oesophageal cancer remains elusive. This study evaluated the role of [F-18]fluorodeoxyglucose (FDG) PET-CT in assessing tumour and nodal response as a prognostic marker. Methods: This was a single-centre UK cohort study. From 2006 to 2014, patients with oesophageal cancer staged with PET-CT before NAC, and restaged by CT or PET-CT before resection, were included. Pathological tumour response was evaluated using Mandard regression grades. Metabolic tumour and nodal responses (mTR and mNR respectively) were quantified using absolute and threshold reductions. Results: Among 294 included patients, mTR and mNR independently predicted prognosis before surgery. After surgery, mNR (but not mTR), pathological tumour response, resection margin status and pathological node category predicted prognosis. Patients with FDG-avid nodal disease after NAC were at high risk of recurrence/death at 1 and 2 years (43 and 71 per cent respectively; P = 0.030 and P = 0.025 versus patients without avid nodes), and had a worse prognosis than patients with non-avid nodal metastases: hazard ratio 4.19 (95 per cent c.i. 1.87 to 9.40) and 2.11 (1.12 to 3.97) respectively versus patients without nodal metastases. Considering mTR and mNR response separately improved prognostication. Conclusion: mNR is a novel prognostic factor, independent of conventional N status. Primary and nodal tumours may respond discordantly and patients with FDG-avid nodes after NAC have a poor prognosis.

引用

页码：408 / 417

页数：10

共 43 条

[21]

Findlay J.M., Gillies R.S., Franklin J.M., Teoh E.J., Jones G.E., di Carlo S., Et al., Restaging oesophageal cancer after neoadjuvant therapy with F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery, Eur Radiol, 26, pp. 3519-3533, (2016)

[22]

Findlay J.M., Bradley K.M., Maile E.J., Braden B., Maw J., Phillips-Hughes J., Et al., Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy, Br J Surg, 102, pp. 1488-1499, (2015)

[23]

Gillies R.S., Middleton M.R., Maynard N.D., Bradley K.M., Gleeson F.V., Additional benefit of <sup>18</sup>F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer, Eur Radiol, 21, pp. 274-280, (2011)

[24]

Siewert J.R., Stein H.J., Feith M., Adenocarcinoma of the esophago-gastric junction, Scand J Surg, 95, pp. 260-269, (2006)

[25]

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial, Lancet, 359, pp. 1727-1733, (2002)

[26]

Phase 2 Trial of Neo-adjuvant Oxaliplatin and 5-Fluorouracil in Oesophageal Cancer: EudraCT 2005-001834-34, (2006)

[27]

OE05 a Randomised Controlled Trial Comparing Standard Chemotherapy Followed by Resection, Versus, ECX Chemotherapy Followed by Resection in Patients with Resectable Adenocarcinoma of the Oesophagus, (2008)

[28]

ST03: a Randomised Phase II/III Trial of Perioperative Chemotherapy With or Without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-Oesophageal Junction, (2008)

[29]

Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, pp. 11-20, (2006)

[30]

Gillies R.S., Simpkin A., Sgromo B., Marshall R.E., Maynard N.D., Left thoracoabdominal esophagectomy: results from a single specialist center, Dis Esophagus, 24, pp. 138-144, (2011)

← 1 2 3 4 5 →